医学院


 
导师代码: 20333
导师姓名: 许川
性    别:
特    称:
天府峨眉计划特聘专家;重庆市巴渝学者
职    称: 教授
学    位: 医学博士学位
属    性: 专职
电子邮件: xuchuan100 @ 163.com

学术经历:  

个人简介:   许 川 教授/研究员 副主任医师 医学博士,博士后,博士研究生导师,博士后合作导师 电子科技大学医学院附属肿瘤医院/四川省肿瘤医院 肿瘤临床研究中心 主任;肿瘤整合医学中心 副主任医师 电子科技大学医学院 教授 从事肿瘤综合治疗、个体化与靶向治疗、免疫治疗等临床诊疗与转化医学工作。美国德克萨斯大学M.D Anderson癌症中心、维克森林大学医学院肿瘤中心研究学者;法国Leon Berard肿瘤医院/国家里昂癌症研究院访问学者。在建立正常干细胞(SCs)与肿瘤干细胞(CSCs)的富集筛选策略基础上,发现线粒体超激活状态是维持干细胞“干性”的重要因素,阐明了线粒体自噬在干细胞自我更新、分化发育及肿瘤演进、复发耐药中发挥主导作用的确切机制;解析了一系列“干性”分子及相关信号通路靶蛋白在重塑肿瘤恶性表型中的机制并探索了早期诊断、治疗及预后中的应用价值。揭示了CSCs 与免疫细胞的相互作用,肿瘤免疫逃逸发生的时空规律特征及调控机制,为探寻肺癌共性与特异性的早诊筛查标志物和开发靶向治疗药物提供了新思路和靶点。 四川省海内外高层次人才天府峨眉计划引进“四川省特聘专家”(2018) 重庆市政府“巴渝学者”讲座教授(2019) 四川省杰出青年基金获得者(2020) 电子科技大学青年人才学术托举工程杰出创新人才项目(2020) 国家科学技术进步奖二等奖一项(2019年) 中华医学科技奖一等奖一项(2018年) 近年以第一/通讯作者在Nature Immunology、Journal of Clinical Investigation、Advanced Functional Materials、Cancer Research、Bioactive Materials、Signal Transduction and Targeted Therapy等SCI期刊发表论文三十余篇,影响因子≥20分1篇,影响因子≥10≤20分6篇;影响因子≥5≤10分11篇;总被引用2000余次,单篇最高他引166次。 主持国家自然科学基金(4项)、国家博士后科学基金面上与特别资助(3项)、国家重点研发计划子课题等项目5项。 学术任职: 中国临床肿瘤学会转化医学专委会 常务委员 中国临床肿瘤学会非小细胞肺癌专委会 委员 中国抗癌协会肿瘤支持治疗专委会 委员 中国临床肿瘤学会患者教育专委会 委员 中国抗癌协会肿瘤代谢专委会 青年委员 中国抗癌协会肿瘤营养专委会肿瘤免疫营养学组 副组长 中国抗癌协会肿瘤代谢专委会细胞代谢与炎癌转化学组 副组长 四川省抗癌协会理事会 理事 四川省细胞生物学会理事会 理事 四川省抗癌协会肿瘤精准医学与临床转化专委会 主任委员 四川省医疗卫生与健康促进会第一届呼吸与危重症专委会 副主任委员 四川省抗癌协会肿瘤免疫治疗专业委员会 常务委员 四川省抗癌协会呼吸病学专委会 常务委员 四川省抗癌协会第二届抗癌药物专委会 常务委员 担任Cell Metabolism、Advanced Science、Advanced Functional Materials、Signal Transduct Target Therapy、Cancer Letters等期刊审稿人, Curr Cancer Drug & Targ、Frontiers in Molecular Biosciences特邀编辑

科研项目:   1.肿瘤微环境新型分子探针与成像技术在肿瘤脑转移中的应用研究(2022—2024)电子科技大学医工结合项目院方负责人(40万) 2.基于量子级联激光器的人体呼出气体检测技术在肺癌等疾病诊断中的应用研究 国家重点研发计划(2021—2024)子课题负责人(100万) 3.基于“互联网+”肺癌及肺小结节患者一体化诊疗全程管理的应用示范推广研究 成都市科技项目重点研发支撑计划(2020—2022)课题骨干(100万) 4.肿瘤干细胞与免疫微环境调控机制研究 四川省杰出青年基金(2020—2022) 主持,在研(40万) 5.肿瘤干细胞与免疫微环境调控机制研究 2019-2022科研启动基金(2019—2022) 主持(300万) 6.芫花提取物PFP2降解IAP遏制耐药肿瘤细胞免疫逃逸的功能机制研究(81873048) 国家自然科学基金面上项目(2019—2022) 主持(57万) 7.Developing novel immunotherapy strategies for lung cancer. Wake Forest Innovations(2016—2021) 主持(780000USD) 8.Esrrb—Sox-5正反馈调控环路在维持肺癌干细胞高侵袭表型中的作用机制研究(81572892) 国家自然科学基金面上项目(2016— 2019) 主持,结题(57万) 9.NR3B2在维持肺癌干细胞高侵袭表型中的作用机制研究(2015JQO0 55) 四川省杰出青年基金培育(2015-2017)主持,结题(10万) 10.Wg基因对家蚕脂肪细胞增殖分化的调控机制研究(sklsgb2013023) 国家重点实验室开放基金(2014-2015)主持,结题(20万) 11.以中药新藤黄酸为基础配伍化疗药物抗肺癌细胞增殖的作用机制研究(2014-F-080) 四川省中医药科技支撑项目(2014-2015)主持,结题(5万) 12.IGF-1R与Wnt协同调控β-catenin/Pou5f1/Sox2复合体形成维持肺癌细胞"干性"的机制(81272598)国家自然科学基金面上项目(2013—2016) 主持,结题(70万) 13.肺癌干细胞自我更的新机制(2012T50852) 国家博士后科学基金特别资助(2012T50852) (2012—2013) 主持,结题(15万) 14.IGF-1R信号通路在Pou5f1促肺癌干细胞侵袭中的作用及机制(20110491853) 国家博士后科学基金面上项目(2011—2012) 主持,结题(3万) 15.国家自然科学基金青年项目 30800900 (2009—2011)主持,结题(21万)

研究成果:   通讯作者文章: [1]Wu H, Li H, Liu Y, Liang J, Liu Q, Xu Z, Cheng Z, Zhang X, Zhang K, Xu C. Blockading a new NSCLC immunosuppressive target by pluripotent autologous tumor vaccines magnifies sequential immunotherapy. Bioactive Materials. 2021. doi: 10.1016/j. bioactmat.2021.10.048. IF: 14.593 [2]Shi Y, Wu M, Liu Y, Hu L, Wu H, Xie L, Liu Z, Wu A, Chen L, Xu C. ITGA5 Predicts Dual-Drug Resistance to Temozolomide and Bevacizumab in Glioma. Frontiers in Oncology, 2021: 5294. doi.org/10.3389/fonc.2021.769592. IF:6.244 [3]Wu H, Wang T, Liu Y, Li X, Xu S, Wu C, Zou H, Cao M, Jin G, Lang J, Wang B, Liu B, Luo X, Xu C. Mitophagy promotes sorafenib resistance through hypoxia-inducible ATAD3A dependent Axis. J Exp Clin Cancer Res. 2020 Dec 7;39(1):274. doi: 10.1186/ s13046-020-01768-8. PMID: 33280610; PMCID: PMC7720487.IF:11.161 [4]Wang J, Wu H, Song G, Yang D, Huang J, Yao X, Qin H, Chen Z, Xu Z, Xu C. A Novel Imidazopyridine Derivative Exerts Anticancer Activity by Inducing Mitochondrial Pathway-Mediated Apoptosis. Biomed Res Int. 2020 Aug 25;2020:4929053. doi: 10.1155 /2020/4929053. PMID: 32908894; PMCID: PMC7468608.IF:3.411 [5]Yao Q, Zou L, Lan H, Luo S, Lu S, Lang J, Xu C. Initial Experience of a Tele-radiotherapy System for Training Radiation Oncologists in Rural Areas. J Cancer Educ. 2020 Jul 28. doi: 10.1007/s13187-020-01836-9. Epub ahead of print. PMID: 32725417.IF:2.037 [6]Zhang K, Li H, Lang J, Li X, Yue W, Yin Y, Du D, Fang Y, Wu H, Zhao Y, Xu C. Quantum yield‐engineered biocompatible probes illuminate lung tumor based on viscosity confinement‐mediated antiaggregation.Advanced Functional Materials. 2019.29(44), 1905124. doi:10.1002/adfm.201905124.IF:18.808 [7]Zou H, Chen Q, Zhang A, Wang S, Wu H, Yuan Y, Wang S, Yu J, Luo M, Wen X, Cui W, Fu W, Yu R, Chen L, Zhang M, Lan H, Zhang X, Xie Q, Jin G, Xu C. MPC1 deficiency accelerates lung adenocarcinoma progression through the STAT3 pathway. Cell Death Dis. 2019 Feb 15;10(3):148. doi: 10.1038/s41419-019-1324-8. PMID: 30770798; PMCID: PMC6377639.IF:8.469 [8]Zou H, Wang S, Wang S, Wu H, Yu J, Chen Q, Cui W, Yuan Y, Wen X, He J, Chen L, Yu R, Zhang M, Lan H, Jin G, Zhang X, Bian X, Xu C. SOX5 interacts with YAP1 to drive malignant potential of non-small cell lung cancer cells. Am J Cancer Res. 2018 May 1;8(5):866-878. PMID: 29888108; PMCID: PMC5992510.IF:6.166 [9]Li Y, Lei J, Xu J, Tang DY, Chen ZZ, Zhu J, Xu C. A facile method for building fused quinoxaline-quinolinones via an acidless post-Ugi cascade reaction.?Chinese Chemical Letters. 2017 28(3), 541-545. doi: 10.1016/j.cclet.2016.10.027IF:6.779 共同通讯文章: [1]Liu Y, Wu H, Luo T, Luo Q, Meng Z, Shi Y, Li F, Liu M, Peng X, Liu J, Xu C, Tang W. The SOX9-MMS22L Axis Promotes Oxaliplatin Resistance in Colorectal Cancer. Front Mol Biosci. 2021 May 27;8:646542. doi: 10.3389/fmolb.2021.646542. PMID: 34124145; PMCID: PMC8191464.IF:5.246 [2]Luo Q, He W, Mao T, Leng X, Wu H, Li W, Deng X, Zhao T, Shi M, Xu C, Han Y. MMS22L Expression as a Predictive Biomarker for the Efficacy of Neoadjuvant Chemoradiotherapy in Oesophageal Squamous Cell Carcinoma. Front Oncol. 2021 Sep 30;11:711642. doi: 10.3389/fonc.2021.711642. PMID: 34660277; PMCID: PMC8514954.IF:6.244 [3]Zhou J, Zhou F, Chu X, Zhao J, Wu Y, Zhao W, Xu C, Su C. Non-alcoholic fatty liver disease is associated with immune checkpoint inhibitor-based treatment response in patients with non-small cell lung cancer with liver metastases. Transl Lung Cancer Res. 2020 Apr;9(2):316-324. doi: 10.21037/tlcr.2020.04.15. PMID: 32420071; PMCID: PMC7225134.IF:6.498 [4]Yu J, Wu C, Wu Q, Huang J, Fu W, Xie X, Li W, Tang W, Xu C, Jin G. PCYT1A suppresses proliferation and migration via inhibiting mTORC1 pathway in lung adenocarcinoma. Biochem Biophys Res Commun. 2020 Aug 20;529(2):353-361. doi: 10. 1016/j.bbrc.2020. 05.164. Epub 2020 Jul 1. PMID: 32703435.IF:3.575 [5]Liu P, Zhu C, Luo J, Lan S, Su D, Wang Q, Wei Z, Cui W, Xu C, Yang X. Par6 regulates cell cycle progression through enhancement of Akt/PI3K/GSK-3β signaling pathway activation in glioma. FASEB J. 2020 Jan;34(1):1481-1496. doi: 10.1096/fj. 201901629RR. Epub 2019 Dec 2. PMID: 31914615. IF:5.191 [6]Xu Z, Ding Y, Meng J, Tang D, Li Y, Lei J, Xu C, Chen Z. Facile construction of hydantoin scaffolds via a post-Ugi cascade reaction.?Synlett. 2018 29(16), 2199-2202. doi:?10.1055/s-0037-1610234.IF:2.454 [7]Wang T, Wu H, Liu S, Lei Z, Qin Z, Wen L, Liu K, Wang X, Guo Y, Liu Q, Liu L, Wang J, Lin L, Mao C, Zhu X, Xiao H, Bian X, Chen D, Xu C, Wang B. SMYD3 controls a Wnt-responsive epigenetic switch for ASCL2 activation and cancer stem cell maintenance. Cancer Lett. 2018 Aug 28;430:11-24. doi:?10.1016/j.canlet.2018.05.003. Epub 2018 May 8. PMID: 29746925.IF:8.679 [8]Xin YH, Bian BS, Yang XJ, Cui W, Cui HJ, Cui YH, Zhang X, Xu C, Bian XW. POU5F1 enhances the invasiveness of cancer stem-like cells in lung adenocarcinoma by upregulation of MMP-2 expression. PLoS One. 2013 Dec 30;8(12):e83373. doi: 10.1371 /journal.pone.00 83373. PMID: 24386189; PMCID: PMC3875455.IF:3.240 第一作者文章: [1]Chuan Xu, Guoxiang Jin, Hong Wu, Wei Cui, Yu-Hui Wang, Rajesh Kumar Manne, Gui-hua Wang, Wei-na Zhang, Xian Zhang, Fei Han, Zhen Cai, Bo-Syong Pan, Che-Chia Hsu, An-mei Zhang, Jie Long, Hongbo Zou, Shuang Wang, Xiaodan Ma, Jinling Duan, Bin Wang, Weihui Liu, Hai-tao Lan, Qing Xiong, Gang Xue, Zhongzhu Chen, Zhigang Xu, Mark E. Furth, Sarah E. Haigh Molin, Yong Lu, Dan Xie, Xiu-wu Bian*, Hui-Kuan Lin*. SIRPγ-expressing cancer stem-like cells promote immune escape of lung cancer via Hippo signaling. J Clin Invest. 2022 Mar 1; 132(5): e141797. [2]Jin G, Xu C, Zhang X, Long J, Rezaeian AH, Liu C, Furth ME, Kridel S, Pasche B, Bian XW, Lin HK. Atad3a suppresses Pink1-dependent mitophagy to maintain homeostasis of hematopoietic progenitor cells. Nat Immunol. 2018 Jan;19(1):29-40. doi: 10.1038/s41590 -017-0002-1. Epub 2017 Nov 21. PMID: 29242539; PMCID: PMC5905408.IF:25.606 [3]Liu WH, Ren LN, Chen T, Liu LY, Jiang JH, Wang T, Xu C, Yan HT, Zheng XB, Song FQ, Tang LJ. Abdominal paracentesis drainage ahead of percutaneous catheter drainage benefits patients attacked by acute pancreatitis with fluid collections: a retrospective clinical cohort study. Crit Care Med. 2015 Jan;43(1):109-19. doi: 10.1097/CCM.0000 000000000606. PMID: 25251762.IF:7.598 [4]Xu C, Xie D, Yu SC, Yang XJ, He LR, Yang J, Ping YF, Wang B, Yang L, Xu SL, Cui W, Wang QL, Fu WJ, Liu Q, Qian C, Cui YH, Rich JN, Kung HF, Zhang X, Bian XW. β-Catenin/POU5F1/SOX2 transcription factor complex mediates IGF-I receptor signaling and predicts poor prognosis in lung adenocarcinoma. Cancer Res. 2013 May 15;73(10): 3181-9. doi: 10.1158/0008-5472.CAN-12-4403. Epub 2013 Mar 28. PMID: 23539445.IF:12.701 [5]Xu C, Chen JA, Qiu Z, Zhao Q, Luo J, Yang L, Zeng H, Huang Y, Zhang L, Cao J, Shu W. Ovotoxicity and PPAR-mediated aromatase downregulation in female Sprague-Dawley rats following combined oral exposure to benzo[a]pyrene and di-(2-ethylhexyl) phthalate. Toxicol Lett. 2010 Dec 15;199(3):323-32. doi: 10.1016/j.toxlet.2010.09.015. PMID: 20920559.IF:4.372 [6]Xu C, Zhang JJ, Chen JA, Cao B, Shu WQ, Cao J. Evaluation of ovotoxicity in female mice caused by organic extracts in tap water from Jialing River in Chongqing, China. Birth Defects Res B Dev Reprod Toxicol. 2010 Feb;89(1):26-33. doi: 10.1002/bdrb.20219. PMID: 20035550.IF:2.344 [7]Xu C, Shu WQ, Qiu ZQ, Chen JA, Zhao Q, Cao J. Protective effects of green tea polyphenols against subacute hepatotoxicity induced by microcystin-LR in mice. Environ Toxicol Pharmacol. 2007 Sep;24(2):140-8. doi: 10.1016/j.etap.2007.04.004. Epub 2007 Apr 21. PMID: 21783802.IF:4.860 综述: [1]Li W, Li F, Zhang X, Lin H, Xu C. Insights into the post-translational modification and its emerging role in shaping the tumor microenvironment. Signal Transduct Target Ther. 2021 Dec 20;6(1):422. doi: 10.1038/s41392-021-00825-8. PMID: 34924561.IF:18.187 [2]Li Y, Hu L, Xu C. Kirsten rat sarcoma inhibitors in clinical development against nonsmall cell lung cancer. Curr Opin Oncol. 2021 Oct 22. doi: 10.1097/CCO.0000000000000808. Epub ahead of print. PMID: 34690284.IF:3.645 [3]Li W, Peng X, Lang J, Xu C. Targeting Mouse Double Minute 2: Current Concepts in DNA Damage Repair and Therapeutic Approaches in Cancer. Front Pharmacol. 2020 May 7;11:631. doi: 10.3389/fphar.2020.00631. PMID: 32477121; PMCID: PMC7232544.IF:5.810 [4]Wang D, Wu H, Liang X, Liu J, Li H, Xu C. Advances in the Application of Intestinal Flora in Anti-Tumor Therapy.?Journal of Nutritional Oncology. 2019?4(2). doi: 10.34175/jno2019 02002. [5]Qi XW, Zhang F, Wu H, Liu JL, Zong BG, Xu C, Jiang J. Wilms' tumor 1 (WT1) expression and prognosis in solid cancer patients: a systematic review and meta-analysis. Sci Rep. 2015 Mar 9;5:8924. doi:?10.1038/srep08924. PMID: 25748047; PMCID: PMC4352850.IF:4.379 [6]Wu H, Qi XW, Yan GN, Zhang QB, Xu C, Bian XW. Is CD133 expression a prognostic biomarker of non-small-cell lung cancer? A systematic review and meta-analysis. PLoS One. 2014 Jun 18;9(6):e100168. doi: 10.1371/journal.pone.0100168. PMID: 24940615; PMCID: PMC4062503.IF:3.240 参与论文: [1]Hsu CC, Zhang X, Wang G, Zhang W, Cai Z, Pan BS, Gu H, Xu C, Jin G, Xu X, Manne RK, Jin Y, Yan W, Shao J, Chen T, Lin E, Ketkar A, Eoff R, Xu ZG, Chen ZZ, Li HY, Lin HK. Inositol serves as a natural inhibitor of mitochondrial fission by directly targeting AMPK. Mol Cell. 2021 Sep 16;81(18):3803-3819.e7. doi: 10.1016/j.molcel.2021.08.025. PMID: 34547240; PMCID: PMC8462099.IF:17.970 [2]Luo J, Lu C, Feng M, Dai L, Wang M, Qiu Y, Zheng H, Liu Y, Li L, Tang B, Xu C, Wang Y, Yang X. Cooperation between liver-specific mutations of pten and tp53 genetically induces hepatocarcinogenesis in zebrafish. J Exp Clin Cancer Res. 2021 Aug 20;40(1):262. doi: 10.1186/s13046-021-02061-y. PMID: 34416907; PMCID: PMC83779 46. IF:11.161 [3]Hu CS, Huang JH, Yang DL, Xu C, Xu ZG, Tan HB, Chen ZZ. Lentivirus-mediated silencing of CNTN1 enhances gefitinib sensitivity by reversing epithelial-mesenchymal transition in lung adenocarcinoma A549 cells. Oncol Lett. 2021 Jun;21(6):433. doi: 10.3892/ol.2021.12694. Epub 2021 Mar 31. PMID: 33868471; PMCID: PMC8045161.IF:2.967 [4]Liu M, Wu H, Liu Y, Tan Y, Wang S, Xie S, Xiang R, Liang J, Zhang R, Xu C, He J, Li Q. MiR-326 mediates malignant biological behaviors of lung adenocarcinoma by targeting ZEB1. Sci Prog. 2021 Apr-Jun;104(2):368504211009379. doi: 10.1177/0036850421100 9379. PMID: 33913391. [5]Zou L, Chen X, Xu C, Xing L, Xie Y. Design and Preliminary Experience of a Tele-Radiotherapy System for a Medical Alliance in China. Telemed J E Health. 2020 Feb;26(2):235-243. doi: 10.1089/tmj.2018.0323. Epub 2019 Mar 20. PMID: 30892144.IF:3.536 [6]Zhang W, Wang G, Xu ZG, Tu H, Hu F, Dai J, Chang Y, Chen Y, Lu Y, Zeng H, Cai Z, Han F, Xu C, Jin G, Sun L, Pan BS, Lai SW, Hsu CC, Xu J, Chen ZZ, Li HY, Seth P, Hu J, Zhang X, Li H, Lin HK. Lactate Is a Natural Suppressor of RLR Signaling by Targeting MAVS. Cell. 2019 Jun 27;178(1):176-189.e15. doi: 10.1016/j.cell.2019.05.003. Epub 2019 May 30. PMID: 31155231; PMCID: PMC6625351.IF:41.582 [7]Wang G, Long J, Gao Y, Zhang W, Han F, Xu C, Sun L, Yang SC, Lan J, Hou Z, Cai Z, Jin G, Hsu CC, Wang YH, Hu J, Chen TY, Li H, Lee MG, Lin HK. SETDB1-mediated methylation of Akt promotes its K63-linked ubiquitination and activation leading to tumorigenesis. Nat Cell Biol. 2019 Feb;21(2):214-225. doi: 10.1038/s41556-018-0266-1. Epub 2019 Jan 28. Erratum in: Nat Cell Biol. 2021 Jun;23(6):676. PMID: 30692626; PMCID: PMC6414065.IF:28.824 [8]Pan Y, Gao G, Chen X, Tian Q, Wu F, Liu Q, Wang Y, Jiang T, Liu Y, Li X, Yang S, Xu C, Su C, Zhou F, Ren S, Zhou C. Larger tumors are associated with inferior progression-free survival of first-line EGFR-tyrosine kinase inhibitors and a lower abundance of EGFR mutation in patients with advanced non-small cell lung cancer. Thorac Cancer. 2019 Apr;10(4):686-694. doi: 10.1111/1759-7714.12986. Epub 2019 Feb 22. PMID: 30793872; PMCID: PMC6449243.IF:3.500 [9]Han F, Li CF, Cai Z, Zhang X, Jin G, Zhang WN, Xu C, Wang CY, Morrow J, Zhang S, Xu D, Wang G, Lin HK. The critical role of AMPK in driving Akt activation under stress, tumorigenesis and drug resistance. Nat Commun. 2018 Nov 9;9(1):4728. doi: 10.1038/ s41467-018-07188-9. PMID: 30413706; PMCID: PMC6226490.IF:14.919 [10]Zhang X, Li CF, Zhang L, Wu CY, Han L, Jin G, Rezaeian AH, Han F, Liu C, Xu C, Xu X, Huang CY, Tsai FJ, Tsai CH, Watabe K, Lin HK. TRAF6 Restricts p53 Mitochondrial Translocation, Apoptosis, and Tumor Suppression. Mol Cell. 2016 Nov 17;64(4):803-814. doi: 10.1016/j.molcel.2016.10.002. Epub 2016 Nov 3. PMID: 27818144; PMCID: PMC 5541903.IF:17.970 [11]Liao WL, Li SQ, Wang J, Zhang ZY, Yang ZW, Xu D, Xu C, Lan HT, Chen ZZ, Xu ZG. An Efficient and Facile Method for the Synthesis of Benzimidazoisoquinoline Derivatives via a Multicomponent Reaction. ACS Comb Sci. 2016 Jan 11;18(1):65-9. doi: 10.1021/ acscombsci. 5b00145. Epub 2015 Dec 18. PMID: 26634875.IF:3.784 [12]Liu WH, Wang T, Yan HT, Chen T, Xu C, Ye P, Zhang N, Liu ZC, Tang LJ. Predictors of percutaneous catheter drainage (PCD) after abdominal paracentesis drainage (APD) in patients with moderately severe or severe acute pancreatitis along with fluid collections. PLoS One. 2015 Feb 6;10(2):e0115348. doi: 10.1371/journal.pone.0115348. PMID: 2565 9143; PMCID: PMC4319763.IF:3.240 [13]Peng L, Bian XW, Li DK, Xu C, Wang GM, Xia QY, Xiong Q. Large-scale RNA-Seq Transcriptome Analysis of 4043 Cancers and 548 Normal Tissue Controls across 12 TCGA Cancer Types. Sci Rep. 2015 Aug 21;5:13413. doi: 10.1038/srep13413. PMID: 26 292924; PMCID: PMC4544034.IF:4.379 [14]Wang Z, Wang B, Shi Y, Xu C, Xiao HL, Ma LN, Xu SL, Yang L, Wang QL, Dang WQ, Cui W, Yu SC, Ping YF, Cui YH, Kung HF, Qian C, Zhang X, Bian XW. Oncogenic miR-20a and miR-106a enhance the invasiveness of human glioma stem cells by directly targeting TIMP-2. Oncogene. 2015 Mar 12;34(11):1407-19. doi: 10.1038/onc.2014.75. Epub 2014 Apr 7. PMID: 24704830.IF:9.867 [15]Tang C, Yang L, Jiang X, Xu C, Wang M, Wang Q, Zhou Z, Xiang Z, Cui H. Antibiotic drug tigecycline inhibited cell proliferation and induced autophagy in gastric cancer cells. Biochem Biophys Res Commun. 2014 Mar 28;446(1):105-12. doi: 10.1016/j.bbrc. 2014.02.043. Epub 2014 Feb 28. PMID: 24582751.IF:3.575 [16]Wang B, Wang Q, Wang Z, Jiang J, Yu SC, Ping YF, Yang J, Xu SL, Ye XZ, Xu C, Yang L, Qian C, Wang JM, Cui YH, Zhang X, Bian XW. Metastatic consequences of immune escape from NK cell cytotoxicity by human breast cancer stem cells. Cancer Res. 2014 Oct 15;74(20):5746-57. doi: 10.1158/0008-5472.CAN-13-2563. Epub 2014 Aug 27. PMID: 25164008.IF:12.701 [17]Shi Y, Chen C, Zhang X, Liu Q, Xu JL, Zhang HR, Yao XH, Jiang T, He ZC, Ren Y, Cui W, Xu C, Liu L, Cui YH, Yu SZ, Ping YF, Bian XW. Primate-specific miR-663 functions as a tumor suppressor by targeting PIK3CD and predicts the prognosis of human glioblastoma. Clin Cancer Res. 2014 Apr 1;20(7):1803-13. doi: 10.1158/1078-043 2.CCR-13-2284. Epub 2014 Feb 12. PMID: 24523440.IF:12.531 [18]Shan J, Shen J, Liu L, Xia F, Xu C, Duan G, Xu Y, Ma Q, Yang Z, Zhang Q, Ma L, Liu J, Xu S, Yan X, Bie P, Cui Y, Bian XW, Qian C. Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. Hepatology. 2012 Sep;56(3):1004-14. doi: 10.1002/hep.25745. Epub 2012 Jul 12. PMID: 22473773.IF:17.425 [19]Chen JA, Li X, Li J, Cao J, Qiu Z, Zhao Q, Xu C, Shu W. Degradation of environmental endocrine disruptor di-2-ethylhexyl phthalate by a newly discovered bacterium, Microbacterium sp. strain CQ0110Y. Appl Microbiol Biotechnol. 2007 Mar;74(3):676-82. doi: 10.1007/s00253-006-0700-3. Epub 2006 Nov 7. PMID: 17089119.IF:4.813

专业研究方向:  
专业名称 研究方向 招生类别
107200生物医学工程 02疾病临床研究 博士
100200临床医学 07肿瘤学 硕士


学院列表
01  信息与通信工程学院
02  电子科学与工程学院
03  材料与能源学院
04  机械与电气工程学院
05  光电科学与工程学院
06  自动化工程学院
07  资源与环境学院
08  计算机科学与工程学院
09  信息与软件工程学院
10  航空航天学院
11  数学科学学院
12  物理学院
13  医学院
14  生命科学与技术学院
15  经济与管理学院
16  公共管理学院
17  外国语学院
18  马克思主义学院
21  基础与前沿研究院
22  通信抗干扰技术国家级重点实验室
23  电子科学技术研究院
28  深圳高等研究院